This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss The ADVOR trial, possibly the only randomized, placebo controlled trial of sequential nephron blockade ever. Could the use of acetazolamide in acute decompensated heart failure make a difference?
It’s back! The NephJC Summer Book Club with Walter Isaacson’s book which is part Jennifer Doudna biography and part an examination of CRISPER technology and its implications.
This week, we will discuss the ADMIRAL DNA, which sells the cell-free donor derived DNA as the shiny new thing which will make diagnostics easy in kidney transplants. Or will it?
This week, we have a practice changing study about the treatment of mild hypertension during pregnancy. Join us on Tuesday (9 EDT) and Wednesday (9 IST).
We have a long awaited huge update on the ISPD peritonitis guidelines. Bugs change and we need to change how we treat them. We break down the evidence for you in this summary
This week, we will discuss the intricate analysis using target trial emulation - applied for the initiation of dialysis in CKD. Let’s fix problems of lead time and immortal time bias.
This week, we will discuss two trials with a joint IPNA JC session. PREDNOS 2 explores and explodes the steroids use in URTI to prevent relapse practice, while another noninferiority trial reports use of lower dose steroids in managing relapses.